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GENETICALLY ENGINEERED EQUINE 
INFLUENZA VIRUS AND USES THEREOF 
This application is a national stage application under 35 
U.S.C. §371 of International Patent Application No. PCT/ 
US2005/019383, ?led Jun. 5, 2005, which claims the bene?t 
of US. Provisional Application No. 60/653,588, ?led Feb. 
15, 2005, entitled “Genetically Engineered Equine In?uenza 
Virus and Uses Thereof,” each of which is incorporated by 
reference herein in its entirety. 
This invention was made, in part, with United States Gov 
ernment support. The United States Government may have 
certain rights in this invention. 
1. FIELD OF THE INVENTION 
The present invention relates, in general, to attenuated 
equine in?uenza viruses having an impaired ability to antago 
nize the cellular interferon (IFN) response, and the use of 
such attenuated viruses in vaccine and pharmaceutical for 
mulations. In particular, the invention relates to attenuated 
equine in?uenza viruses having modi?cations to an equine 
NS1 gene that diminish or eliminate the ability of the NS1 
gene product to antagonize the cellular IFN response. These 
viruses replicate in vivo, but demonstrate decreased virulence 
and increased attenuation, and therefore are well suited for 
use in live virus vaccines and pharmaceutical formulations. 
2. BACKGROUND 
2.1 In?uenza Virus 
Virus families containing enveloped single-stranded RNA 
of the negative-sense genome are classi?ed into groups hav 
ing non-segmented genomes (Paramyxoviridae, Rhabdoviri 
dae, Filoviridae and Borna Disease Virus) or those having 
segmented genomes (Orthomyxoviridae, Bunyaviridae and 
Arenaviridae). The Orthomyxoviridae family, described in 
detail below, and used in the examples herein, includes the 
viruses of in?uenza, types A, B and C viruses, as well as 
Thogoto and Dhori viruses and infectious salmon anemia 
Virus. 
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The in?uenza virions consist of an internal ribonucleopro 
tein core (a helical nucleocapsid) containing the single 
stranded RNA genome, and an outer lipoprotein envelope 
lined inside by a matrix protein (M1). The segmented genome 
of in?uenza A virus consists of eight molecules (seven for 
in?uenza C) of linear, negative polarity, single-stranded 
RNAs which encode eleven polypeptides, including: the 
RNA-dependent RNA polymerase proteins (PB2, PB1 and 
PA) and nucleoprotein (NP) which form the nucleocapsid; the 
matrix membrane proteins (M1, M2); two surface glycopro 
teins which project from the lipid containing envelope: 
hemagglutinin (HA) and neuraminidase (NA); the nonstruc 
tural protein (NS1) and nuclear export protein (NEP); and 
proapoptotic factor PB 1 -F2. Transcription and replication of 
the genome takes place in the nucleus and assembly occurs 
via budding on the plasma membrane. The viruses can reas 
sort genes during mixed infections. 
In?uenza virus adsorbs via HA to sialyloligosaccharides in 
cell membrane glycoproteins and glycolipids. Following 
endocytosis of the virion, a conformational change in the HA 
molecule occurs within the cellular endosome which facili 
tates membrane fusion, thus triggering uncoating. The 
nucleocapsid migrates to the nucleus where viral mRNA is 
transcribed. Viral mRNA is transcribed by a unique mecha 
nism in which viral endonuclease cleaves the capped 5'-ter 
minus from cellular heterologous mRNAs which then serve 
as primers for transcription of viral RNA templates by the 
viral transcriptase. Transcripts terminate at sites 15 to 22 
bases from the ends of their templates, where oligo(U) 
sequences act as signals for the addition of poly(A) tracts. Of 
the eight viral RNA molecules so produced, six are monocis 
tronic messages that are translated directly into the proteins 
representing HA, NA, NP and the viral polymerase proteins, 
PB2, PB1 and PA. The other two transcripts undergo splicing, 
each yielding two mRNAs which are translated in different 
reading frames to produce M1, M2, NS1 and NEP. The PB1 
segment encodes a second protein, the nonstructural PB1-F2 
protein, by using an alternative ATG. In other words, the eight 
viral RNA segments code for eleven proteins: nine structural 
and two nonstructural. A summary of the genes of the in?u 
enza virus and their protein products is shown in Table I 
below. 
TABLE I 
INFLUENZA VIRUS GENOME RNA SEGMENTS AND CODING 
ASSIGNMENTS“ 
Lengthd 
Lengch7 Encoded (Amino Molecules 
Segment (Nucleotides) PolypeptideC Acids) Per Virion Comments 
1 2341 PB2 759 30—60 RNA transcriptase component; 
host cell RNA cap binding 
2 2341 PBl 757 30—60 RNA transcriptase component; 
initiation of transcription 
PB 1—F2 87 Proapoptotic factor 
3 2233 PA 716 30—60 RNA transcriptase component 
1778 HA 5 66 500 Hemagglutinin; trimer; envelope 
glycoprotein; mediates 
attachment to cells 
5 1565 NP 498 1000 Nucleoprotein; associated with 
RNA; structural component of 
RNA transcriptase 
6 1413 NA 454 100 Neuralninidase; tetralner; 
envelope glycoprotein 
7 1027 M1 252 3000 Matrix protein; lines inside of 
envelope 
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TABLE I-continued 
INFLUENZA VIRUS GENOME RNA SEGMENTS AND CODING 
ASSIGNMENTS” 
Length d 
Lengch7 Encoded (Amino Molecules 
Segment (Nucleotides) PolypeptideC Acids) Per Virion Comments 
M2 96 7 Structural protein in plasma 
membrane; spliced mRNA 
8 890 NS 1 230 Nonstructural protein; 
NEP 121 7 Nuclear export protein; spliced 
mRNA 
“Adapted from R. A. Lamb and P. W. Choppin (1983), Annual Review ofBiochemistry, Volume 52, 467-506. 
bFor A/PR/8/34 strain 
Determined by biochemical and genetic approaches 
dDetermined by nucleotide sequence analysis and protein sequencing 
The pathogenicity of in?uenza viruses is modulated by 
multiple virus and host factors. Among the host factors that 
?ght virus infections, the type I interferon (IFNa/B) system 
represents a powerful antiviral innate defense mechanism 
which was established relatively early in the evolution of 
eukaryotic organisms (Garcia-Sastre, 2002, Microbes Infect 
4:647-55). The antiviral IFNa/B, system involves three major 
steps: (i) detection of viral infection and IFNa/B secretion, 
(ii) binding of IFNa/B to its receptors and transcriptional 
induction of IFNa/B-stimulated genes, and (iii) synthesis of 
antiviral enzymes and proteins. Most viruses, however, have 
acquired speci?c genetic information encoding IFNa/B 
antagonist molecules, which effectively block one or more 
steps of the antiviral IFNa/B system. In?uenza A viruses 
express a non-structural protein in infected cells, the NSI 
protein (described in detail, infra), which counteracts the 
cellular IFNa/B response (Garcia-Sastre et al., 1998, Virol 
ogy 252:324-30). 
The in?uenza A virus genome contains eight segments of 
single-stranded RNA of negative polarity, coding for two 
nonstructural and nine structural proteins. The nonstructural 
protein NSI is abundant in in?uenza virus infected cells, but 
has not been detected in virions. NSI is a phosphoprotein 
found in the nucleus early during infection and also in the 
cytoplasm at later times of the viral cycle (King et al., 1975, 
Virology 64:378). Studies with temperature-sensitive (ts) 
in?uenza mutants carrying lesions in the NS gene suggested 
that the NSI protein is a transcriptional and post-transcrip 
tional regulator of mechanisms by which the virus is able to 
inhibit host cell gene expression and to stimulate viral protein 
synthesis. Like many other proteins that regulate post-tran 
scriptional processes, the NSI protein interacts with speci?c 
RNA sequences and structures. The NSI protein has been 
reported to bind to different RNA species including: vRNA, 
poly-A, U6 snRNA, 5' untranslated region as of viral mRNAs 
and ds RNA (Qiu et a1, 1995, RNA 1: 304; Qiu et al., 1994, J. 
Virol. 68: 2425; Hatada Fukuda 1992, JGenVirol. 73:3325-9. 
Expression of the NSI protein from cDNA in transfected cells 
has been associated with several effects: inhibition of nucleo 
cytoplasmic transport of mRNA, inhibition of pre-mRNA 
splicing, inhibition of host mRNA polyadenylation and 
stimulation of translation of viral mRNA (Fortes, et al., 1994, 
EMBO J. 13: 704; Enami et al., 1994, J. Virol. 68: 1432; de la 
Luna et al., 1995, J. Virol. 69:2427; Lu et al., 1994, Genes 
Dev. 8:1817; Park et al., 1995, J. Biol Chem. 270, 28433; 
Nemeroff et al., 1998, Mol. Cell. 1:1991; Chen et al., 1994, 
EMBO J. 18:2273-83). In particular, the NSI protein has 
three domains that have been reported to have a number of 
regulatory functions during in?uenza virus infection. The 
amino -terminal 73 amino acids are responsible for binding to 
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RNAs (Qian et al., 1995, RNA 1:948-956), particularly 
double stranded RNAs, conferring to the virus the ability to 
escape the interferon (x/[3 response (Donelan et al., 2003, J. 
Virol. 77:13257-66). The central portion of the protein inter 
acts with the eukaryotic translation initiation factor 4GI 
facilitating preferential translation of viral mRNAs over host 
mRNAs (Aragon et a1, 2000, Mol. Cell Biol. 20:6259-6268). 
The carboxy-terminus or the effector domain has been shown 
to inhibit host mRNA processing, speci?cally, inhibition of 
host mRNA polyadenylation (Nemeroff et al., 1998, Mol. 
Cell 1:991 -1000), binding to poly(A) tails of mRNA inhibit 
ing nuclear export (Qiu and Krug, 1994, J. Virol. 68:2425 
2432) and inhibition of pre-mRNA splicing (Lu et al., 1994, 
Genes Dev. 8:1817-1828). 
Studies of human recombinant in?uenza virus lacking the 
NSI gene (delNSl) showed that this virus could only repli 
cate in IFN-incompetent systems such as STAT1—/— mice or 
Vero cells; thus the NSI protein is responsible for IFN antago 
nist activity (Garcia-Sastre et al., 1998, Virology 252:324 
330). Also, it has been shown that human in?uenza viruses 
with truncated NSI proteins are attenuated in mice (Egorov et 
al., 1998, J. Virol. 72:6437-6441) and provide protection 
against wild-type challenge (Talon et al., 2000, Proc. Natl. 
Acad. Sci. USA 97:4309-4314). 
2.2 Equine In?uenza Virus 
Equine in?uenza virus belongs to the Orthomyxoviridae 
family of In?uenza typeA viruses. It is an enveloped, negative 
sense RNA virus, with a segmented, single-stranded genome. 
There are two distinct subtypes of equine in?uenza virus: 
Subtype 1, H7N7, ?rst isolated in Prague in 1956 (Sovinova 
et al., 1958, Acta Virol. 2:52-61), and subtype 2. H3N8, ?rst 
isolated in Miami in 1963 (Wadell et al., 1963, J. Am. Vet. 
Med. Assoc. 143:587-590). It is believed that subtype 1 is no 
longer in circulation as the last con?rmed outbreak caused by 
this virus was in 1978 (Webster, R. G., 1993, Equine Vet. 
25:537-538). 
Equine in?uenza has been recognized as a common 
malady of the horse for centuries and is considered the most 
economically important respiratory disease of the equine in 
countries with substantial breeding and racing industries. In a 
1998 study of infectious upper respiratory tract disease in 151 
horses in Colorado, it was found that the pathogen was 
responsible for two-thirds of equine viral respiratory infec 
tions (Mumford et al., 1998, J. Am. Vet. Med. Assoc. 213: 
385-390). 
Vaccination is the most effective method of prophylaxis 
against in?uenza, designed to elicit a protective antibody 
response and resistance to re-infection. In?uenza viruses 
undergo continual antigenic variation of the surface glyco 
proteins, HA and NA. Thus, in order to be effective, in?uenza 
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vaccines require frequent updating to include relevant circu 
lating strains of equine in?uenza virus. The most widely used 
vaccines are inactivated (killed) whole equine in?uenza virus 
preparations. However, the ability of some of these vaccines 
to provide protection against disease has been proven to be 
quite poor in e?icacy studies. In one study, Morley et al. 
demonstrated that horses vaccinated with an inactivated alu 
minum phosphate adjuvanted vaccine did not differ signi? 
cantly from those given a placebo, in the severity of the 
clinical disease they suffered during an in?uenza epidemic 
(Morley et al., 1999, J. Am. Vet. Med. Assoc. 215161-66). 
However, a cold-adapted (ts), modi?ed-live attenuated in?u 
enza virus vaccine (Flu-AvertTM I.N., Heska Corp.) has 
shown more promising results. E?icacy trials of this vaccine 
showed animals were clinically protected three months after 
vaccination (Lunn et al., 2001, J. Am. Vet. Med. Assoc. 218: 
900-906) and had reduced severity of disease with signi?cant 
clinical protection six months after vaccination (Townsend, 
2001, Equine Vet. J. 33:637-643). 
2.3 Attenuated Viruses 
Inactivated virus vaccines are prepared by “killing” the 
viral pathogen, e.g., by heat or formalin treatment, so that it is 
not capable of replication. Inactivated vaccines have limited 
utility because they do not provide long lasting immunity and, 
therefore, afford limited protection. An alternative approach 
for producing virus vaccines involves the use of attenuated 
live virus vaccines. Attenuated viruses are capable of repli 
cation but are not pathogenic, and, therefore, provide for 
longer lasting immunity and afford greater protection. How 
ever, the conventional methods for producing attenuated 
viruses involve the chance isolation of host range mutants, 
many of which are temperature sensitive; e.g., the virus is 
passaged through unnatural hosts, and progeny viruses which 
are immunogenic, yet not pathogenic, are selected. 
A conventional substrate for isolating and growing in?u 
enza viruses for vaccine purposes are embryonated chicken 
eggs. In?uenza viruses are typically grown during 2-4 days at 
37° C. in 10-12 day old eggs. Although most of the human 
primary isolates of in?uenza A and B viruses grow better in 
the amniotic sac of the embryos, after 2 to 3 passages the 
viruses become adapted to grow in the cells of the allantoic 
cavity, which is accessible from the outside of the egg (Mur 
phy, B. R., and R. G. Webster, 1996. Orthomyxoviruses pp. 
1397-1445. In Fields Virology. Lippincott-Raven P. A.). 
Recombinant DNA technology and genetic engineering 
techniques, in theory, would afford a superior approach to 
producing an attenuated virus since speci?c mutations could 
be deliberately engineered into the viral genome. However, 
the genetic alterations required for attenuation of viruses are 
not known or predictable. In general, the attempts to use 
recombinant DNA technology to engineer viral vaccines have 
mostly been directed to the production of subunit vaccines 
which contain only the protein subunits of the pathogen 
involved in the immune response, expressed in recombinant 
viral vectors such as vaccinia virus or baculovirus. More 
recently, recombinant DNA techniques have been utilized in 
an attempt to produce herpes virus deletion mutants or polio 
viruses which mimic attenuated viruses found in nature or 
known host range mutants. Until 1990, the negative strand 
RNA viruses were not amenable to site-speci?c manipulation 
at all, and thus could not be genetically engineered. 
Although attenuated in?uenza viruses are bene?cial 
because they are immunogenic and not pathogenic, they are 
dif?cult to propagate in conventional substrates for the pur 
poses of making vaccines. Furthermore, attenuated viruses 
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may possess virulence characteristics that are so mild as to not 
allow the host to mount an immune response su?icient to 
meet subsequent challenges. 
An alternative approach for producing virus vaccines to the 
inactivated virus vaccines in which the viral pathogen is 
“killed”, involves the use of attenuated live virus vaccines 
which are capable of replication but are not pathogenic. Live 
vaccines which are administered intranasally may have 
advantages over their inactivated counterparts. Firstly, live 
vaccines are thought to induce improved cross-reactive cell 
mediated cytotoxicity as well as a humoral antibody 
response, providing better protection than inactivated vac 
cines (Gorse and Belshe, 1990, J. Clin. Microbiol. 2812539 
2550; and Gorse et al., 1995, J. Infect. Dis. 172:1-10). Sec 
ondly, protective immunity to equine in?uenza virus is likely 
to involve mucosal IgA response which is not seen with 
traditional intramuscularly administered vaccines (Nelson et 
al., 1998, Vaccine 16:1306-1313). Finally, live vaccines also 
have the advantage of intranasal administration which avoids 
the swelling and muscle soreness occasionally associated 
with the intramuscular administration of inactivated adju 
vanted vaccines. These live vaccines have been reported to 
induce not only humoral responses against homotypic in?u 
enza virus but also crossreactive cell-mediated cytotoxicity. 
Further advantages of live vaccines include the ease of intra 
nasal administration, induction of mucosal immunity, longer 
lasting immunity, and its cost effectiveness. Equine in?uenza 
virus replicates in the nasal mucosa, thus an intranasally 
administered vaccine may be a preferable route of inoculation 
to elicit this response (Soboll et al., 2003, Vaccine 2113081 
3092). These are all important considerations regarding 
potential equine in?uenza vaccines. 
Thus, new and more effective vaccines and immunogenic 
formulations for preventing equine in?uenza virus infections 
generated by such technology are needed. 
3. SUMMARY OF THE INVENTION 
The present invention provides attenuated equine in?uenza 
viruses having an impaired ability to antagonize the cellular 
interferon (IFN) response, methods for producing such 
attenuated equine in?uenza viruses, and the use of such 
viruses in vaccine and pharmaceutical formulations. Such 
viruses are capable of generating an immune response and 
creating immunity but not causing illness or causing fewer 
and/or less severe symptoms, i.e., the viruses have decreased 
virulence. Therefore, they are ideal candidates for live virus 
vaccines. Moreover, the attenuated viruses can induce a 
robust IFN response which has other biological consequences 
in vivo, affording protection against subsequent infectious 
diseases and/ or inducing antitumor responses. Therefore, the 
attenuated viruses can be used pharmaceutically, for the pre 
vention or treatment of other infectious diseases and/ or IFN 
treatable diseases. 
The invention is based, in part, on the Applicants’ discov 
ery that equine in?uenza viruses engineered to contain or 
containing a deletion(s) in the N81 gene have impaired rep 
lication relative to wild-type equine in?uenza viruses. Sur 
prisingly, and contrary to results seen with human in?uenza 
virus in mouse models, the length of the N81 protein does not 
correlate with the level of attenuation of the equine in?uenza 
virus. Applicants have discovered that with equine in?uenza, 
a mutant virus with the shortest NSl protein is the least 
attenuated. In other words, equine in?uenza viruses contain 
ing shorter deletions in the N81 gene exhibit a greater attenu 
ation in vivo than equine in?uenza viruses containing longer 
deletions in their NSl gene, or wild-type equine in?uenza 
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viruses. Applicants have further discovered that the recombi 
nant equine in?uenza viruses are impaired in their ability to 
inhibit IFN production in vitro, and they do not replicate as 
e?iciently as the parental recombinant strain in embryonated 
hen eggs, in MDCK cells or in an in vivo mouse model. While 
not intending to be bound to any theory or explanation for the 
mechanism of action of the equine in?uenza virus NSl dele 
tion mutants in vivo, the attenuated features of such viruses 
are presumably due to their levels of N81 protein expression, 
their ability to induce a robust cellular IFN response, and their 
impaired ability to antagonize such a response. However, the 
bene?cial features of such viruses may not be solely attribut 
able to their effect on the cellular interferon response. Indeed, 
alterations in other activities associated with NSl, such as, 
alteration of pre-mRNA splicing, inhibition of cellular 
mRNA polyadenylation, poly(A)-containing mRNA nucleo 
cytoplasmic transport, and stimulation of viral protein syn 
thesis, may contribute to the desired attenuated phenotype 
achieved by the introduction of mutations in the N81 gene of 
equine in?uenza virus. 
An attenuated equine in?uenza virus of the present inven 
tion comprises a mutation in an equine in?uenza NSl gene 
that diminishes the ability of the N81 gene product to antago 
nize the cellular interferon response. In one embodiment, an 
attenuated equine in?uenza virus of the invention comprises 
a genome comprising a mutation in an equine in?uenza virus 
NSl gene that diminishes the ability of the N81 gene product 
to antagonize a cellular interferon response, and permits the 
attenuated virus, at a multiplicity of infection (MOI) of 
between 0.0005 and 0.001, 0.001 and 0.01, 0.01 and 0.1, or 
0.1 and 1, or a MOI of 0.0005, 0.0007, 0.001, 0.005, 0.01, 
0.05, 0.1, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 
6.0, to grow to titers between approximately 1 to approxi 
mately 100 fold, approximately 5 to approximately 80 fold, 
approximately 20 to approximately 80 fold, or approximately 
40 to approximately 80 fold, approximately 1 to approxi 
mately 10 fold, approximately 1 to approximately 5 fold, 
approximately 1 to approximately 4 fold, approximately 1 to 
approximately 3 fold, approximately 1 to approximately 2 
fold, approximately 3 to approximately 15 fold, or approxi 
mately 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 
55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold lower than 
wild-type equine in?uenza virus in cells (e.g., cells of human, 
mouse, chicken, rat, birds, horse (e.g., equine fetal kidney 
cells or equine dermal cells), etc.), as determined approxi 
mately 2 to 10 days, 3 to 7 days, 3 to 5 days, or 2, 3, 4, 5, 6, 7, 
8, 9, 10 days post-infection when propagated under the same 
conditions. The titers of attenuated and wild-type equine 
in?uenza viruses can be determined utilizing any technique 
well-known in the art or described herein (e.g., hemaggluti 
nation assays, plaque assays, tissue culture infectious dose 50 
(TCID50), egg infectious dose 50 (EID50), etc.), and the 
viruses can be propagated under conditions described herein 
or well-known in the art (e.g., in horse cells, MDCK cells 
(e. g., in MEM, 10% v/v fetal calf serum (FCS), 1% penicillin/ 
streptomycin at 37° C. in a 5% CO2 humidi?ed incubator) or 
embryonated chicken eggs (e.g., in a stationary incubator at 
370 C. with 55% relative humidity). Alternatively, the viruses 
can be propagated in cells (e.g., in horse cells, MDCK cells, 
etc.) that are grown in serum-free or serum reduced (e.g., 
TPCK trypsin) medium. 
In a speci?c embodiment, an attenuated equine in?uenza 
virus of the invention comprises a genome comprising a 
mutation in an equine in?uenza virus NSl gene that dimin 
ishes the ability of the N81 gene product to antagonize a 
cellular interferon response, and permits the attenuated virus, 
at a multiplicity of infection (MOI) of between 0.0005 and 
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0.001, 0.001 and 0.01, 0.01 and 0.1, or 0.1 and 1, or a MOI of 
0.0005, 0.0007, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 1.5, 2.0, 
2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0, to grow to titers between 
approximately 1 to approximately 100 fold, approximately 5 
to approximately 80 fold, approximately 20 to approximately 
80 fold, or approximately 40 to approximately 80 fold, 
approximately 1 to approximately 10 fold, approximately 1 to 
approximately 5 fold, approximately 1 to approximately 4 
fold, approximately 1 to approximately 3 fold, approximately 
1 to approximately 2 fold, approximately 3 to approximately 
15 fold, or approximately 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20,25, 
30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold 
lower than wild-type equine in?uenza virus in horse cells 
(e.g., equine fetal kidney cells (e. g., FEK or EFK-2 cells)), as 
determined approximately 2 to 10 days, 3 to 7 days, 3 to 5 
days, or 2, 3, 4, 5, 6, 7, 8, 9, 10 days post-infection when 
propagated under the same conditions. The titers of attenu 
ated and wild-type equine in?uenza viruses can be deter 
mined utilizing any technique well-known in the art or 
described herein, (e.g., hemagglutination assays, plaque 
assays, etc.) and the viruses can be propagated under condi 
tions described herein or well-known in the art (e. g., in horse 
cells, MDCK cells (e.g., in MEM, 10% v/v fetal calf serum 
(FCS), 1% penicillin/streptomycin at 370 C. in a 5% CO2 
humidi?ed incubator) or embryonated chicken eggs (e.g., in a 
stationary incubator at 370 C. with 55% relative humidity). 
The equine in?uenza viruses used in accordance with the 
invention may be selected from naturally occurring strains, 
variants or mutants; mutagenized viruses (e.g., viruses gen 
erated by exposure to mutagens, repeated passages and/or 
passage in non permissive hosts); reassortants; and/or geneti 
cally engineered viruses (e.g., using the “reverse genetics” 
and helper-free plasmid based techniques) having the desired 
phenotypeii.e., an impaired ability to antagonize the cellu 
lar IFN response. The naturally occurring strains, variants or 
mutants, reassortments and/ or genetically engineered viruses 
with the desired interferon antagonist phenotype can be 
selected based on differential growth in cells (e.g., cells of 
human, mouse, chicken, rat, birds, horse, etc.) in other assays 
described below. In certain embodiments, the equine in?u 
enza viruses of the invention are genetically engineered 
viruses. In other embodiments, the equine in?uenza viruses 
of the invention are not naturally occurring strains, variants or 
mutants and/ or reassortments. 
In a speci?c embodiment, an attenuated equine in?uenza 
virus of the invention comprises a genome comprising a 
mutation in an equine in?uenza virus NSl gene that dimin 
ishes the ability of the N81 gene product to antagonize a 
cellular interferon response, and permits the attenuated virus, 
at a multiplicity of infection (MOI) of between 0.0005 and 
0.001, 0.001 and 0.01, 0.01 and 0.1, or 0.1 and 1, or a MOI of 
0.0005,0.0007,0.001,0.005,0.01,0.05,0.1,0.5,1.0,1.5,2.0, 
2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0, to grow to titers between 
approximately 1 to approximately 100 fold, approximately 5 
to approximately 80 fold, approximately 20 to approximately 
80 fold, or approximately 40 to approximately 80 fold, 
approximately 1 to approximately 10 fold, approximately 1 to 
approximately 5 fold, approximately 1 to approximately 4 
fold, approximately 1 to approximately 3 fold, approximately 
1 to approximately 2 fold, approximately 3 to approximately 
15 fold or approximately 1, 2, 3, 4, 5, 6, 7, 8, 10, 15,20, 25,30, 
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold 
lower than wild-type equine in?uenza virus in horse cells 
(e.g., equine fetal kidney cells (e.g., FEK or EFK-2 cells)) as 
determined by a hemagglutination assay of BALF from 
horses or supematants of horse cells approximately 2 to 10 
days, 3 to 7 days, 3 to 5 days, or 2, 3, 5, 6, 7, 8, 9, 10 days 
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post-infection or when the viruses are plaqued on Madin 
Darby canine kidney (MDCK) cells. In one embodiment, the 
growth of an attenuated equine in?uenza virus of the inven 
tion is compared to a particular standard or reference, e.g., 
wild-type equine in?uenza virus A/Eq/KY/5/02. In accor 
dance with these embodiments, the attenuated virus may be 
genetically engineered to contain or express non-equine 
in?uenza virus nucleic acid sequences such, e.g., an epitope 
of a foreign pathogen or a tumor antigen. Preferably, the 
non-equine in?uenza virus sequences do not include a nucleic 
acid sequence that alters the attenuated phenotype of the 
virus. Accordingly, nucleic acid sequences encoding pro 
teins, polypeptides or peptides with interferon antagonizing 
activity are preferably not engineered into an equine in?uenza 
V1rus. 
The invention provides attenuated equine in?uenza viruses 
comprising a genome comprising at least two, at least three, at 
least four or more mutations in two, three, four or more equine 
in?uenza virus genes, wherein at least one of the mutations is 
in the N81 gene and contributes to or is responsible (directly 
or indirectly) for the attenuation of the virus and/or the dimin 
ished ability of the virus to antagonize a cellular interferon 
response. In one embodiment, an attenuated equine in?uenza 
virus of the invention comprises a genome comprising at least 
two, at least three, at least four or more mutations in two, 
three, four or more equine in?uenza virus genes, wherein at 
least one of the mutations is in the N81 gene and is respon 
sible for the diminished ability of the N81 gene product to 
antagonize a cellular interferon response, and permits the 
attenuated virus, at a MOI of between 0.0005 and 0.001, 
0.001 and 0.01, 0.01 and 0.1, or 0.1 and 1, or a MOI of0.0005, 
0.0007, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 1.5, 2.0, 2.5, 
3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0, to grow to titers between 
approximately 1 to approximately 100 fold, approximately 5 
to approximately 80 fold, approximately 20 to approximately 
80 fold, or approximately 40 to approximately 80 fold, 
approximately 1 to approximately 10 fold, approximately 1 to 
approximately 5 fold, approximately 1 to approximately 4 
fold, approximately 1 to approximately 3 fold, approximately 
1 to approximately 2 fold, approximately 3 to approximately 
15 fold or approximately 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, 25, 30, 
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold 
lower than wild-type equine in?uenza virus in cells (e.g., cells 
of human, mouse, chicken, rat, birds, horse, etc.), as deter 
mined by, e. g., hemagglutination assays, approximately 2 to 
10 days, 3 to 7 days, 3 to 5 days, or 2, 3, 5, 6, 7, 8, 9, 10 days 
post-infection when the viruses are propagated under the 
same conditions. In a speci?c embodiment, an attenuated 
equine in?uenza virus of the invention comprises a genome 
comprising at least two, at least three, at least four or more 
mutations in two, three, four or more equine in?uenza virus 
genes, wherein at least one of the mutations is in the N81 gene 
and is responsible for the diminished ability of the N81 gene 
product to antagonize a cellular interferon response, and per 
mits the attenuated virus, at a MOI of between 0.0005 and 
0.001, 0.001 and 0.01, 0.01 and 0.1, or 0.1 and 1, or a MOI of 
0.0005, 0.0007, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 1.5, 2.0, 
2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0, to grow to titers between 
approximately 1 to approximately 100 fold, approximately 5 
to approximately 80 fold, approximately 20 to approximately 
80 fold, or approximately 40 to approximately 80 fold, 
approximately 1 to approximately 10 fold, approximately 1 to 
approximately 5 fold, approximately 1 to approximately 4 
fold, approximately 1 to approximately 3 fold, approximately 
1 to approximately 2 fold, approximately 3 to approximately 
15 fold or approximately 1, 2, 3, 4, 5, 6, 7, 8, 10, 15,20, 25,30, 
35,40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold 
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lower than wild-type equine in?uenza virus in horse cells, as 
determined by, e.g., hemagglutination assays, approximately 
2 to 10 days, 3 to 7 days, 3 to 5 days, or 2, 3, 5, 6, 7, 8, 9, 10 
days post-infection when the viruses are propagated under the 
same conditions (e.g., in MDCK cells). In another embodi 
ment, an attenuated equine in?uenza virus of the invention 
comprises a genome comprising at least two, three, four or 
more mutations in two, three, four or more equine in?uenza 
virus genes, wherein at least one of the mutations is in the N81 
gene and is responsible for the attenuation of the virus, and 
permits the attenuated virus, at a MOI of between 0.0005 and 
0.001, 0.001 and 0.01, 0.01 and 0.1, or 0.1 and 1, or a MOI of 
0.0005,0.0007,0.001,0.005,0.01,0.05,0.1,0.5,1.0,1.5,2.0, 
2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0, to grow to titers between 
approximately 1 to approximately 100 fold, approximately 5 
to approximately 80 fold, approximately 20 to approximately 
80 fold, or approximately 40 to approximately 80 fold, 
approximately 1 to approximately 10 fold, approximately 1 to 
approximately 5 fold, approximately 1 to approximately 4 
fold, approximately 1 to approximately 3 fold, approximately 
1 to approximately 2 fold, approximately 3 to approximately 
15 fold or approximately 1, 2, 3, 4, 5, 6, 7, 8, 10, 15,20, 25,30, 
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold 
lower than wild-type equine in?uenza virus in horse cells, as 
determined by, e.g., hemagglutination assays, approximately 
2 to 10 days, 3 to 7 days, 3 to 5 days, or 2, 3, 5, 6, 7, 8, 9, 10 
days post-infection when the viruses are propagated under the 
same conditions (e.g., in MDCK cells). In accordance with 
these embodiments, the attenuated virus has an impaired 
interferon antagonist phenotype and may be genetically engi 
neered to contain or express non-equine in?uenza virus 
nucleic acid sequences, such as, e.g., an epitope of a foreign 
pathogen (e.g., epitopes of Equine Reovirus (Orbivirus), 
Arteritis Virus, Equine Herpes Virus (EHVl, EHV2, EHV3, 
EHV4 and EHV5), Equine Papova Virus, Retrovirus, Aden 
ovirus, African Horse Sickness Vlrus, Shipping Fever Virus, 
West Nile Virus, Equine Encephalitis Virus, Vesicular Stoma 
titis Virus (V SV), Equine Rhinovirus, and Hendra Virus), and 
antigenic determinants of non viral equine pathogens such as 
bacteria, including, but not limited to, Closlridia sp., Salmo 
nella sp., E. coli, Streptococcus equi, Taylorella equigenilalis 
(CEM), Klebsiella pneumoniae and Pseudomonas aerugi 
nosa, Dermalophilus congolensis, or a tumor antigen such as 
equine sarcoid Mc1 (P55 or P124), horse prostate kallikrein 
(HPK), carcinoembryonic antigen (CEA), breast cancer anti 
gen such as EGFR (epidermal growth factor receptor), HER2 
antigen (p185HER2), HER2 neu epitope, cancer antigen-50 
(CA-50), cancer antigen 15-3 (CA15-3) associated with 
breast cancer, carcinoma associated antigen (CAA), mela 
noma antigen, and melanoma associated antigens 100, 25, 
and 150). Preferably, the non-equine in?uenza virus 
sequences (heterologous sequences) do not include a nucleic 
acid sequence that alters the attenuated phenotype of the 
virus. Accordingly, nucleic acid sequences encoding pro 
teins, polypeptides or peptides with interferon antagonizing 
activity are preferably not engineered into the equine in?u 
enza virus. 
Mutations in the equine in?uenza virus NSl gene comprise 
(alternatively, consist of) any mutation that results in the 
desired phenotype (i.e., an impaired ability to antagonize a 
cellular interferon response). Examples of the type of muta 
tions that can be included in or introduced into an equine 
in?uenza virus NSl gene include, but are not limited to, 
deletions, substitutions, insertions and combinations thereof. 
One or more mutations can be located anywhere throughout 
the N81 gene, i.e., in the regulatory, non-coding and/or cod 
ing regions (e.g., the amino-terminus and/or the carboxy 


































